Option chain shows key data for Global Systems Dynamics Inc Warrants (01/04/2026)'s stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Global Systems Dynamics Inc Warrants (01/04/2026).

Global Systems Dynamics Inc Warrants (01/04/2026) (OTC:GSDWW) Stock, Option Chain

Global Systems Dynamics Inc Warrants (01/04/2026)

Soho House &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) shares are trading higher after the company received a $9.00 per share acquisition offer from a new third-party consortium, an 83% premium to the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42576367/soho-house-co-inc-announcement-on-offer-from-a-third-party-consortium-to-acquire-the-company" rel="noreferrer noopener">December 18, 2024, closing price</a>.
Supported by the company&#8217;s Executive Chairman, Ron Burkle and The Yucaipa Companies, the offer follows a strategic review by Yucaipa and its advisors, aiming to better reflect the company&#8217;s inherent value.
In response to the offer, which is contingent on key shareholders rolling over their equity interests, the Board of Directors has established an independent Special Committee to evaluate the proposal.
Also, the company reported third-quarter EPS&nbsp;of $0.00 beating the street view of a loss of $0.01 and sales&nbsp;of $333.4 million missing the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42576891/soho-house-co-inc-announces-third-quarter-2024-results" rel="noreferrer noopener">consensus of $334.87 million</a>.
Membership revenues rose 16.7% year-over-year to <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">$107.4 million in the quarter</a>.
In the third quarter, total members increased 4.8% year-over-year to 267,494, and Soho House members grew 13% year-over-year to 208,078.
The membership waitlist remains at a record level of approximately 111,000.
At the end of the third-quarter of 2024, Soho House had cash and cash equivalents, including restricted cash, of $147 million.
During the quarter, the company repurchased approximately 2.3 million shares for $13 million.
Outlook: Soho House updated its FY24 revenue guidance to around $1.2 billion (vs. the consensus estimate of $1.23 billion), narrowing from its <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">previous range of $1.2 billion to $1.25 billion</a>.
Price Action: SHCO shares are up 58.4% at $7.77 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42593013" target="_blank" rel="noreferrer noopener">Luigi Mangione Faces Extradition, Possible Federal Charges May Carry Death Penalty</a></li>
</ul>
Photo via Shutterstock.

Earnings

Equities

News

Guidance

Small Cap

Movers

SHCO

Soho House Jumps On Receiving Acquisition Offer With 83% Premium

Shares of Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) are trading flat on Thursday, but remain in a downtrend.
If the stock eventually reaches levels around $95.00, there is a good chance it reverses and heads higher. As you can see on the chart, this is what happened in late November. This is why our technical analysis team has made it our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-1024x557.png" alt="Merck" class="wp-image-700197" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19115400/14.png 1491w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
There has been a lot of news coming from Merck.
The advanced cancer genomic testing provider Personalis, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) said it received a $50 million equity investment from Merck.&nbsp; When the deal closes, Merck will own 16.5% of Personalis.
Merck also announced that <a href="https://www.benzinga.com/24/12/42554599/whats-going-on-with-merck-shares-wednesday">it is entering the lucrative obesity market</a>. It is licensing rights from Chinese biotech Hansoh Pharmaceutical Group Company Limited&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/HNSPF#OTC">HNSPF</a>)to an investigational oral GLP – 1 receptor.
The chart of Merck offers some simple but valuable technical analysis lessons. Price levels that had been resistance can convert into support. Also, stocks that drop to support have a tendency to rally.
Read Also: <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases">Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases</a>
$119.40 was resistance in May 2023. Some of the investors who sold then were happy when the price fell soon after. They thought they made a good decision.
But in January 2024 the resistance broke and the stock moved higher. When this happened, some of these sellers came to think they made a mistake and decided to buy their shares back if they can do so at the same price they sold them for.
So, when the stock dropped back to around $119.40 in March 2024 they placed buy orders. The large concentration of these orders formed support at the same price that had been resistance.
Similar action occurred at the $111.00 level. It was resistance in August 2023. Then it became support a year later in August 2024.
In July 2022, the $95.00 level was resistance. It converted into support last month, and it may be support again if Merck reaches it.
As you can also see on the chart, sometimes stocks rally after they reach support. This happens when some of the buyers who created the support think they will get outbid. If someone else is willing to pay a higher price, that's who the sellers will go to.
As a result, they increase the prices they are willing to pay. Others see this and do the same. It can cause a snowball effect that pushes the stock higher and it may be about to happen with Merck.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42595485/bitcoin-rebounds-above-102000-post-fed-meeting-us-gdp-hits-31-jobless-claims-drop-treasury-yields-peak-teslas-eu-registrations-fall-41-q4-ev-target-in-doubt-top-headlines-today-while-us-slept">Bitcoin Rebounds Above $102,000 Post-Fed Meeting; Us GDP Hits 3.1%, Jobless Claims Drop, Treasury Yields Peak &#8211; Top Headlines Today While US Slept</a></li>
</ul>
Image: Courtesy of Merck.

Technicals

Trading Ideas

HNSPF

PSNL

Stock Of The Day: Where Does The Merck Downtrend End?

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) with a Buy and maintains $12 price target.

Price Target

Reiteration

Analyst Ratings

IMNN

HC Wainwright & Co. Reiterates Buy on Imunon, Maintains $12 Price Target

Oppenheimer analyst Rayna Kumar maintains Euronet Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEFT#NASDAQ">EEFT</a>) with a Outperform and lowers the price target from $135 to $128.

EEFT

Oppenheimer Maintains Outperform on Euronet Worldwide, Lowers Price Target to $128

Oppenheimer analyst Rayna Kumar upgrades Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) from Perform to Outperform and announces $115 price target.

Upgrades

Oppenheimer Upgrades Block to Outperform, Announces $115 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and maintains $80 price target.

CLDX

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target

Whales with a lot of money to spend have taken a noticeably bullish stance on Schlumberger.
Looking at options history for Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) we detected 17 trades.
If we consider the specifics of each trade, it is accurate to state that 47% of the investors opened trades with bullish expectations and 47% with bearish.
From the overall spotted trades, 12 are puts, for a total amount of $798,050 and 5, calls, for a total amount of $1,117,614.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $25.0 and $47.5 for Schlumberger, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Schlumberger's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Schlumberger's significant trades, within a strike price range of $25.0 to $47.5, over the past month.
<h3>Schlumberger Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734626823_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$0.99</td>
<td>$0.91</td>
<td>$0.97</td>
<td>$47.50</td>
<td>$970.0K</td>
<td align="right">519</td>
<td>10.0K</td>
</tr>
<tr>
<td>SLB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$10.55</td>
<td>$10.5</td>
<td>$10.55</td>
<td>$47.50</td>
<td>$211.0K</td>
<td align="right">907</td>
<td>122</td>
</tr>
<tr>
<td>SLB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$8.45</td>
<td>$8.25</td>
<td>$8.47</td>
<td>$45.00</td>
<td>$64.3K</td>
<td align="right">663</td>
<td>92</td>
</tr>
<tr>
<td>SLB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.8</td>
<td>$10.7</td>
<td>$10.7</td>
<td>$47.50</td>
<td>$58.8K</td>
<td align="right">907</td>
<td>479</td>
</tr>
<tr>
<td>SLB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.8</td>
<td>$10.7</td>
<td>$10.7</td>
<td>$47.50</td>
<td>$58.8K</td>
<td align="right">907</td>
<td>424</td>
</tr>
</tbody>
</table>

<h3>About Schlumberger</h3>
SLB is the world's premier oilfield-services company as measured by market share. While the industry is mostly fragmented, SLB holds the first or second competitive position in many of the differentiated oligopolies it operates in. Also known as Schlumberger, the company was founded in 1926 by two brothers bearing the same last name. Today it's most known as a global industry leader in innovation, while it focuses its strategy on its three growth engines: its core, digital, and new energy businesses. Over three fourths of its revenue base is tied to international markets, while the company boasts well over $1 billion in digital-related revenue.
In light of the recent options history for Schlumberger, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Schlumberger</h3>
<ul>
<li>With a volume of 5,601,300, the price of SLB is up 0.78% at $37.62. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 29 days.</li>
</ul>
<h3>Professional Analyst Ratings for Schlumberger</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $50.666666666666664.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Schlumberger, targeting a price of $53. 
&#x2A; An analyst from Citigroup persists with their Buy rating on Schlumberger, maintaining a target price of $53. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Schlumberger, which currently sits at a price target of $46. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Schlumberger with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Looking At Schlumberger's Recent Unusual Options Activity

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMP#AMEX">ARMP</a>) with a Buy and maintains $7 price target.

ARMP

HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target

Investors with significant funds have taken a bearish position in First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in FSLR usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 9 options transactions for First Solar. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 33% being bullish and 66% bearish. Of all the options we discovered, 8 are puts, valued at $399,107, and there was a single call, worth $140,000.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $180.0 to $300.0 for First Solar over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for First Solar's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of First Solar's whale trades within a strike price range from $180.0 to $300.0 in the last 30 days. 
<h3>First Solar Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734626818_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$28.75</td>
<td>$28.0</td>
<td>$28.0</td>
<td>$185.00</td>
<td>$140.0K</td>
<td>25</td>
<td align="right">50</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/10/25</td>
<td>$13.9</td>
<td>$13.35</td>
<td>$13.9</td>
<td>$190.00</td>
<td>$90.3K</td>
<td>291</td>
<td align="right">68</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$30.35</td>
<td>$29.6</td>
<td>$30.35</td>
<td>$210.00</td>
<td>$81.9K</td>
<td>837</td>
<td align="right">128</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$127.75</td>
<td>$125.1</td>
<td>$126.85</td>
<td>$300.00</td>
<td>$63.4K</td>
<td>8</td>
<td align="right">5</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$9.45</td>
<td>$8.75</td>
<td>$9.45</td>
<td>$180.00</td>
<td>$47.2K</td>
<td>4.6K</td>
<td align="right">85</td>
</tr>
</tbody>
</table>

<h3>About First Solar</h3>
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.
After a thorough review of the options trading surrounding First Solar, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of First Solar</h3>
<ul>
<li>Trading volume stands at 737,927, with FSLR's price down by -1.57%, positioned at $181.38.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 68 days.</li>
</ul>
<h3>What The Experts Say On First Solar</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $242.33333333333334.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on First Solar with a target price of $250. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for First Solar, targeting a price of $267. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for First Solar, targeting a price of $210. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest First Solar options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

FSLR

First Solar's Options: A Look at What the Big Money is Thinking

Investors with a lot of money to spend have taken a bullish stance on Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DE, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Deere.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 40%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $524,201, and 4 are calls, for a total amount of $397,045.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $380.0 to $470.0 for Deere during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Deere's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Deere's substantial trades, within a strike price spectrum from $380.0 to $470.0 over the preceding 30 days.
<h3>Deere Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734626813_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$14.5</td>
<td>$13.95</td>
<td>$14.5</td>
<td>$390.00</td>
<td>$290.0K</td>
<td>288</td>
<td align="right">200</td>
</tr>
<tr>
<td>DE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$18.6</td>
<td>$17.9</td>
<td>$17.9</td>
<td>$470.00</td>
<td>$177.2K</td>
<td>266</td>
<td align="right">100</td>
</tr>
<tr>
<td>DE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.75</td>
<td>$3.6</td>
<td>$3.75</td>
<td>$450.00</td>
<td>$93.7K</td>
<td>1.9K</td>
<td align="right">268</td>
</tr>
<tr>
<td>DE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$18.5</td>
<td>$18.35</td>
<td>$18.35</td>
<td>$470.00</td>
<td>$91.7K</td>
<td>266</td>
<td align="right">100</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.3</td>
<td>$7.8</td>
<td>$7.8</td>
<td>$420.00</td>
<td>$65.8K</td>
<td>752</td>
<td align="right">88</td>
</tr>
</tbody>
</table>

<h3>About Deere</h3>
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry in their green and yellow livery. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 2,000 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
In light of the recent options history for Deere, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Deere's Current Market Status</h3>
<ul>
<li>Trading volume stands at 472,087, with DE's price up by 0.25%, positioned at $427.05.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 56 days.</li>
</ul>
<h3>What The Experts Say On Deere</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $474.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Deere, targeting a price of $538. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Deere, which currently sits at a price target of $450. 
&#x2A; An analyst from JP Morgan persists with their Neutral rating on Deere, maintaining a target price of $450. 
&#x2A; An analyst from Citigroup has decided to maintain their Neutral rating on Deere, which currently sits at a price target of $470. 
&#x2A; An analyst from UBS persists with their Neutral rating on Deere, maintaining a target price of $462. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Deere, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Market Whales and Their Recent Bets on Deere Options

Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) has outperformed the market over the past 5 years by 15.99% on an annualized basis producing an average annual return of 28.94%. Currently, Eaton Corp has a market capitalization of $135.13 billion. 
Buying $1000 In ETN: If an investor had bought $1000 of ETN stock 5 years ago, it would be worth $3,540.00 today based on a price of $339.44 for ETN at the time of writing.
<h3>Eaton Corp's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734626709_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Eaton Corp 5 Years Ago Would Be Worth Today

NVNI

Nvni Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 496.9%

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and maintains $10 price target.

SGMO

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

Nvni Group Shares Halted On Circuit Breaker To The Upside, Stock Now Up 446.9%

HC Wainwright &amp; Co. analyst Edward White reiterates Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) from Neutral to Neutral.

ACET

HC Wainwright & Co. Reiterates Neutral on Adicet Bioto Neutral

B. Riley Securities analyst Lucas Pipes maintains TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) with a Buy and raises the price target from $8 to $10.

WULF

B. Riley Securities Maintains Buy on TeraWulf, Raises Price Target to $10

Cantor Fitzgerald analyst Matthew Prisco maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Overweight and lowers the price target from $150 to $130.

Cantor Fitzgerald Maintains Overweight on Micron Technology, Lowers Price Target to $130

B. Riley Securities analyst Hal Goetsch reiterates Sezzle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) with a Buy and raises the price target from $353 to $372.

SEZL

B. Riley Securities Reiterates Buy on Sezzle, Raises Price Target to $372

Shares of Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) were climbing in early trading on Thursday, after the nuclear startup announced <a href="https://www.benzinga.com/24/12/42554232/oklo-stock-is-surging-wednesday-morning-whats-going-on">a long-term agreement with Switch</a>.
The company's business model positions it in a "solid spot" for long-term recurring revenues, according to Wedbush.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e00ad4e3513fb0001f03cfd/daniel-ives">Analyst Daniel Ives</a> initiated coverage of Oklo with an Outperform rating and a price target of $26.
Ives noted the company&#8217;s unique business, which brings small modular reactors (SMRs) directly to its customers.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Oklo, backed by OpenAI CEO Sam Altman, has a differentiated business model in that it "sells power, not the reactors, directly to customers under long-term contracts which in turn provide long-term recurring revenues and a streamlined regulatory pathway," the analyst stated.
The company aims to develop its first SMR by 2027, which will be a fast fission reactor that is cooled by liquid metal sodium, with HALEU (High-Assay Low-Enriched Uranium) as a fuel, "which has proven itself as a superior fuel to traditional LEU for its ability to generate further power over time while minimizing waste," he added.
"The AI Revolution is driving significant demand for clean energy to power AI initiatives with necessary computing power expected to grow 10x by 2030 putting OKLO is a great position to capitalize on this elevated demand," Ives further wrote.
Price Action: Shares of Oklo had risen by 2.4% to $18.80 at the time of publication on Thursday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/content/42531058/is-it-time-to-buy-nuclear-energy-stocks-after-the-latest-dip">Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?</a></li>
</ul>
Image: Courtesy of Oklo, Inc.

Analyst Color

Long Ideas

Initiation

OKLO

Oklo Business Model Supports Recurring Revenues, AI Revolution Creates Elevated Demand

On Thursday, Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) released results from the Phase 2b PADOVA study of prasinezumab in early-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42568873/roches-phase-iib-study-of-prasinezumab-missed-primary-endpoint-but-suggests-possible-clinical-bene" rel="noreferrer noopener">stage Parkinson&#8217;s disease</a>.
Partner Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) conducted the 586-subject study investigating prasinezumab in early-stage Parkinson&#8217;s disease patients who had been treated for a minimum of 18 months while on stable symptomatic treatment.
Prasinezumab <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2024-12-19" rel="noreferrer noopener">showed</a> a potential clinical effect in the primary endpoint of time to confirmed motor progression with an HR=0.84 and p=0.0657, missing statistical significance.
The companies said the effect of prasinezumab was more pronounced in a pre-specified analysis in the population treated with levodopa (75% of participants), HR=0.79 and nominal p=0.0431.
Pre-specified supplementary covariate-adjusted analyses of these endpoints demonstrated nominally significant effects on the primary endpoint (HR=0.81; nominal p=0.0334) and in the levodopa subgroup (HR=0.76; nominal p=0.0175).
Consistent positive trends across multiple secondary and exploratory endpoints were also observed. Prasinezumab continues to be well tolerated, and no new safety signals were observed in the study.
The Phase 2 PASADENA and Phase 2b PADOVA open-label extension studies will continue to explore the observed effects in both studies.
Roche will continue to evaluate the data and work together with health authorities to determine the next steps.
Full results from the PADOVA study will be presented at an upcoming medical meeting.
Price Action: PRTA stock is up 32.40% at $15.83 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42561240/salesforces-ai-powered-agentforce-20-spurs-analyst-upgrades-and-growth-optimism" target="_blank" rel="noreferrer noopener">Wall Street Analysts Are Bullish On Salesforce&#8217;s AI Vision &#8211; Here&#8217;s Why</a></li>
</ul>

Comments

Global Systems Dynamics Inc Warrants (01/04/2026)

Global Systems Dynamics Inc Warrants (01/04/2026) (GSDWW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga